FROM CANCER RESEARCH TO CURE











A dedicated oncology cluster

Oslo Cancer Cluster is an oncology research and industry cluster dedicated to accelerating the development of new cancer diagnostics and medicines. We gather almost 70 members from Norway and Northern Europe, representing the entire oncology value chain.


As a Norwegian Centre of Expertise, the Norwegian government partially funds the cluster. An evaluation from 2013 states that Oslo Cancer Cluster is a strong biotech cluster well positioned in the global oncology industry. Major industry trends now offer a unique opportunity to strengthen the cluster's position as a global knowledge and innovation centre.

Oslo Cancer Cluster has core expertise within Immuno-Oncology. The global race in this area makes the cluster well positioned in this field. Several research projects and ongoing clinical trials contribute to an exciting pipeline of novel cancer immunotherapies. Oslo Cancer Cluster established the Norwegian Immuno-Oncology Consortium in 2013 and aims to develop this area further.

Clinical trials in oncology is also an area of high importance for the cluster, and is performed both at the Clinical Cancer Research Unit at Oslo University Hospital and at the Clinical Trial Unit at Haukeland University Hospital.

66 Oslo Cancer Cluster will enable us to seek collaboration with basic scientists, start-ups, biotech companies, clinicians and other pharmaceutical companies. We see Oslo Cancer Cluster as a key driving force for research based innovation in cancer treatment in Norway."

Immuno-Oncology is one of Oslo Cancer Cluster's strongest areas.



Oslo Cancer Cluster's members work closely on six strategic areas to accelerate the development of innovative cancer treatment and diagnostics.

1. COLLABORATIVE NETWORKS & PARTNERING

Stimulate collaborations and partnerships by further develop strong national and international networks.

2. INNOVATION

Stimulate and support innovations and start-up activities.

3. ACCESS TO CAPITAL

Strengthen our member's ability to attract capital.

4. CLINICAL TRIALS EFFICIENCY


Contribute to improved clinical trial efficiency for our members.

5. PUBLIC POLICY

Strengthen governmental focus and improve public policies for the oncology community.

6. TALENT, WORKFORCE & EDUCATION

Engage in development and attraction of top talents to oncology R&D and entrepreneurship.





NETWORKING AND PARTNERING EVENTS HOSTED AND CO-HOSTED BY OSLO CANCER CLUSTER 2014

INTERNATIONAL

International Cancer Cluster Showcase
San Diego, June 22nd, BIO 2014
www.internationalcancercluster.org

Nordic Life Science Days and European Cancer Cluster Partnering 2014: Stockholm, September 7 – 9 www.nlsdays.com

NATIONAL

> 15 tailored events

Please see our Event Calendar for more information:

www.oslocancercluster.no



A power centre for innovative cancer treatment

The vision of the Oslo Cancer Cluster Innovation Park is to create Europe's leading environment for education, research and industry within oncology, while shorten the time it takes to develop new cancer medication and diagnostics. The Innovation Park will open in May 2015 and is on 36 000 m². It brings together the oncology value chain from basic research to industry within the Oslo-area in one place.

The Oslo Cancer Cluster Innovation Park is built next door to the Norwegian Radium Hospital and the Institute of Cancer Research at Oslo University Hospital. These entities, including the Norwegian Cancer Registry, will become one of Europe's top Comprehensive Cancer Centres.

Unlike other Innovation Parks, the Oslo Cancer Cluster Innovation Park will integrate a high school, namely Ullern High School. The collaboration between Ullern High School and Oslo Cancer Cluster started in 2008. Together we aim to educate the researchers and entrepreneurs of tomorrow.

Oslo Cancer Cluster Innovation Park is a reality due to private enthusiasm and the long history of cancer research and treatment performed at the Norwegian Radium Hospital, as well as other academic centres in Norway.

The vision of the Oslo Cancer Cluster Innovation Park is to create one of Europe's leading environments for education, research and industry within oncology, and shorten the time it takes to develop innovative cancer treatments. This kind of Innovation Park does not exist anywhere else."

Oslo Cancer Cluster Innovation Park (to the right), is next door to the Institute of Cancer Research and the Norwegian Radium Hospital.



Fighting cancer everyday

Focused on oncology, the tenants of the Oslo Cancer Cluster Innovation Park work to get bright ideas in the lab to the cancer patients faster than today:

THE CANCER REGISTRY OF NORWAY

The Cancer Registry of Norway was established in 1952, and is one of the oldest national cancer registries in the world. This, combined with the unique personal identification number used in Norway, makes the Cancer Registry's data unique and extremely valuable as source for cancer research and information.

www.kreftregisteret.no

THE INSTITUTE FOR CANCER GENETICS AND INFORMATICS, OSLO UNIVERSITY HOSPITAL:

The Institute was founded in 2004 to be a leading site for the new scientific field merging medicine and computer science into Medical Informatics.

www.medinfo.net

THE NORWEGIAN RADIUM HOSPITAL RESEARCH FOUNDATION

The Research Foundation (RF) invests in and develops companies based on the continuing flow of state-of-the-art innovations in oncology from leading Nordic research institutions. RF is an independent organisation founded in 1986 by The Norwegian Radium Hospital and the Norwegian Ministry of Health.

www.radforsk.no

TARGOVAX

Targovax AS develops active immunotherapy in the form of cancer vaccines. The lead candidate TG01 is currently in a phase II clinical trial in resectable pancreatic cancer. Patients are treated after operation, and the immune system is triggered to recognize cancer specific RAS mutations and kill the cancer cells.

www.targovax.com

OSLO HOSPITAL PHARMACY

The Oslo Hospital Pharmacy, the Norwegian Radium Hospital is responsible for the preparation of cytotoxics and antibodies for the treatment of the cancer patients at the Norwegian Radium Hospital. The Hospital Pharmacy Department also plays a vital role in clinical trials of new cancer drugs.

www.sykehusapotekene.no

DEPARTMENT OF PATHOLOGY

The Department of Pathology at Oslo University Hospital provides laboratory examinations of samples of body tissues for diagnostic and research purposes, and provides pathology services on a local, regional and national basis, serving both internal and external clinics.

The department examines more than 90 000 tissue samples per year, a substantial part of which concerns cancer investigation.

www.oslo-universitetssykehus.no





ULLERN HIGH SCHOOL

Ullern High School was founded in 1900 and will have around 900 students in 2015 when the school moves into the Oslo Cancer Cluster Innovation Park.

The School offers disciplines such as natural sciences, health work, electricity and electronics, media communication, entrepreneurship, work training as well as general studies.

Ullern High School and Oslo Cancer Cluster collaborate closely together and have done so since 2009.

Together we aim to educate the researchers and entrepreneurs of tomorrow. www.ullern.vgs.no



Where budding biotechs bloom

Oslo Cancer Cluster Incubator AS will be an integrated part of the Oslo Cancer Cluster Innovation Park when it opens in May 2015. The Incubator will support promising oncology biotechs to commercialize successfully.

The Oslo Cancer Cluster Incubator will provide a dynamic, creative and professional growth environment for scientists & start-ups. A dedicated Incubator team will offer the tenants of the Incubator, business development services covering key development areas, access to an extensive international network of key industry players, as well as facilitate investor contacts.


The Oslo Cancer Cluster Incubator is already up and running and hosted the first of many training seminars to come in March 2014 on "Development of a new anti-cancer drug product".

Incubator core facilities

- Flexible office and lab space
- Plug & play
- Extensive national & international networks
- Investor network
- One to one guiding & competence building
- · Business development
- IP and regulatory insights
- Meeting series
- Co-localization

Tailored lab space

- Your own lab space or lab
- Shared lab infrastructure
- Reduced costs
- Systematic support and maintenance



66 I applaud what you are achieving in Oslo, very high quality science and medicine focused in oncology, which bodes well for the creation and growth of outstanding new companies."

CONTACT

Oslo Cancer Cluster and Oslo Cancer Cluster Incubator:

Ketil Widerberg, General Manager

Mobile: +47 915 779 90

E-mail: kw@oslocancercluster.no

@KetilWiderberg

Oslo Cancer Cluster Innovation Park

Jónas Einarsson, Initiator of the Oslo Cancer Cluster Innovation Park

Mobile: +47 480 96 355 E-mail: je@radforsk.no

@JEinarsson

www.oslocancercluster.no / www.occinnovationpark.com / www.occincubator.com

COLOPHON

Editor and text: Oslo Cancer Cluster
Photo and illustration credit:
Linda Cartridge, Shutterstock, Dark Arkitekter
Design: Fete typer
Production: Fladby AS
Print run: 1000

Print run: 1000 Published: June 2014

